NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-07-23
Reading NXGL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
NXGL is a speculative growth investment with a medium confidence level. The current thesis state is cautious, as the company is experiencing volatility in management and weak financial performance.
The market currently prices NXGL as cheap compared to its peers, with an expectations gap indicating that it is viewed as justified despite its loss-making status. The low fragility tier suggests that there are no immediate concerns about the stability of the stock.
Fundamentals are likely to remain weak in the near term, as the company continues to report negative operating income. There is a 47% probability of missing earnings expectations, which is a significant risk given the company's history of consecutive misses.
The long-term thesis hinges on the performance of sector bellwethers like ISRG, MDLN, and BDX. If these companies continue to perform well, it could provide a tailwind for NXGL, but any negative guidance from them could lead to further challenges for NXGL.
Over the next 1 to 3 years, NXGL's performance will depend heavily on its ability to navigate its financial challenges and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: The earnings report will show the company's financial health. It also shows how operations are doing.
Confirms one read:The earnings report shows smaller losses or higher revenue than in Q1.
Confirms the other:The earnings report shows larger operating losses or no change in revenue.
Why it matters: Fixing this issue is important for keeping NEXGEL's listing and investor trust.
Confirms:NEXGEL has a clear plan and timeline to fix the Nasdaq listing issue.
Disproves:If progress on the listing issue does not happen, there may be warnings about delisting.
Why it matters: A new CFO can change financial strategies. This could affect future capital allocation and performance.
Confirms one read:Good financial results or higher income from the CFO's plans.
Confirms the other:Ongoing losses or financial issues after the new CFO started.
Why it matters: Fixing the listing issue is important. It helps keep market access and investor trust.
Confirms:The company gets a note from Nasdaq. It shows they meet the $1.00 bid price rule.
Disproves:Nasdaq sends a notice of delisting. This happens because of ongoing non-compliance.
Why it matters: The company raised $1.21M through a private placement. This capital is crucial for ongoing operations.
Confirms one read:Good news on capital use that leads to better financial numbers.
Confirms the other:Bad financial results or more money problems after the recent funding.
Why it matters: Acquiring an exclusive license is a key growth priority. Progress could signal future revenue potential.
Confirms:A press release says the exclusive license was acquired.
Disproves:No news or issues about getting the exclusive license.
Why it matters: If integration is successful, NEXGEL could make much more money. This is important for growth.
Confirms:NEXGEL says the integration of Celularity's products is going well. Revenue may rise by 20% next quarter.
Disproves:If there are delays or revenue from Celularity's products grows less than 10%, it will be a problem.
Why it matters: The earnings report will show if the company is on track to triple revenue as projected.
Confirms one read:Q2 revenue is about $35 million. This shows the acquisition is working.
Confirms the other:Q2 revenue is below $20 million. This shows there are problems with integration and growth.
